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Abstract
Influenza viruses can cause severe life threatening infections in high-risk patients, including
young children, the elderly and patients with compromised immunity due to underlying medi-
cal conditions or immunosuppressive treatment. The impaired immunity of these patients
causes prolonged virus infection and combined with antiviral treatment facilitates the emer-
gence of viruses with resistance mutations. The diverse nature of their immune status
makes them a challenging group to study the impact of influenza virus infection and the effi-
cacy of antiviral therapy. Immunocompromised ferrets may represent a suitable animal
model to assess influenza virus infection and antiviral treatment strategies in immunocom-
promised hosts. Here, ferrets were given a daily oral solution of mycophenolate mofetil,
tacrolimus and prednisolone sodium phosphate to suppress their immune system. Groups
of immunocompromised and immunocompetent ferrets were inoculated with an A/H3N2
influenza virus and were subsequently treated with Oseltamivir or left untreated. Quantita-
tive real-time reverse transcription polymerase chain reaction (qRT-PCR) was performed
on the throat and nose specimens to study virus replication during the course of infection.
All immunocompromised ferrets had prolonged presence of viral RNA and a higher total
amount of virus shedding compared to the immunocompetent ferrets. Although Oseltamivir
reduced the total amount of virus shedding from the nose and throat of treated ferrets, it also
resulted in the emergence of the neuraminidase R292K resistance substitution in all these
animals, as determined by mutation specific RT-PCR and next-generation sequencing. No
additional mutations that could be associated with the emergence of the R292K resistance
mutation were detected. The immunocompromised ferret model can be used to study A/
H3N2 virus shedding and is a promising model to study new antiviral strategies and the
emergence of antiviral resistance in immunocompromised hosts.
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Introduction
Influenza viruses cause infections in millions of individuals worldwide every year. In most
cases, infected patients develop mild clinical symptoms associated with modest virus shedding
that usually resolves within one to two weeks. However, high risk groups, including young
children, the elderly, pregnant woman and individuals with chronic medical conditions such
as obesity, asthma, diabetes and neurological disorders are more likely to develop severe and
complicated influenza, with increased risk of mortality [1, 2]. Recent estimates indicated that
up to 650,000 people die of respiratory diseases linked to seasonal influenza annually [3].
Moreover, various studies have shown that patients with suppressed immunity due to diseases
such as acquired immune deficiency syndrome (AIDS) and autoimmune disorders or due to
the use of immunosuppressive drugs e.g. for chemotherapy or solid organ transplantation also
have an increased risk to develop serious complications following influenza virus infection [1,
4, 5]. Due to their impaired immune status, they are unable to clear viruses efficiently. There-
fore, influenza viruses tend to persist longer and may cause prolonged life threatening infec-
tion in these immunocompromised hosts [5–8].
The primary way to prevent influenza virus infection, especially in high-risk groups, is
through the use of influenza vaccines [9]. Unfortunately, vaccination is not always fully effec-
tive and individuals can still acquire influenza virus infection when the vaccine strains do not
sufficiently match with the circulating viruses. Accordingly, antiviral drugs were developed for
the treatment of patients with confirmed or suspected influenza virus infection to reduce
symptoms and prevent serious complications of influenza [10]. The two classes of antiviral
drugs that are available on the market for the treatment of influenza are the matrix protein 2
(M2) ion channel inhibitors amantadine and rimantadine and the neuraminidase (NA) inhibi-
tors (NAI) Oseltamivir, Zanamivir, Peramivir and Laninamivir [11]. Currently, virtually all
circulating influenza viruses have resistance substitutions against M2 ion channel inhibitors,
whereas the prevalence of resistance substitutions against NAI is low [11, 12]. Therefore, NAI
are currently recommended to treat influenza virus infected patients [11, 13].
The overall efficacy of antiviral drugs to resolve clinical symptoms caused by influenza
virus infection is relatively modest [14]. Accordingly, new antiviral drugs are being developed
that target different steps in the viral replication cycle, such as receptor binding, membrane
fusion, and genome transcription or replication, to treat infection with wildtype and resistant
influenza viruses [15, 16]. Furthermore, various studies have indicated that combination ther-
apy with different antivirals could be more effective, compared to monotherapy, in inhibiting
influenza viruses in immunocompromised patients [17, 18]. The proof of concept for these
drugs that are in the pre-clinical and clinical pipeline as well as combination therapy may be
demonstrated using appropriate animal models, including models that attempt to capture the
situation in immunocompromised patients. It is challenging to assess an optimal regimen of
antiviral therapy for immunocompromised patients, due to the heterogeneity of illnesses, vary-
ing levels of immune suppression and variable course of virus infection among patients in this
group [4, 19]. The majority of randomized clinical trials testing the efficacy of antiviral treat-
ments against influenza virus infection has been conducted in individuals with a competent
immune response [14, 20]. The strategies adapted from these studies have also been used to
treat influenza virus infected immunocompromised patients and they appear to be effective in
these patients [21, 22]. However, virus replication can persist in these patients even after the
administration of antiviral treatment [5, 23]. Additionally, it has been reported that immuno-
compromised patients have a higher risk to acquire antiviral resistance [7, 24, 25]. This may be
due to the prolonged infection or the high virus turnover observed in these patients, which
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provide an increased likelihood of acquiring resistance mutations that are under positive selec-
tion in the presence of antiviral treatment.
Ferrets have been widely uses as a model to investigate influenza virus infection, because
the susceptibility to infection and the range of clinical signs seen in infected ferrets are very
similar to those observed in humans. Moreover, the anatomy of the airways and the distribu-
tion patterns of sialic acid receptor expression in the respiratory tract of ferrets are comparable
to those in humans [26]. Ferrets may also be an appropriate model to study the levels of virus
replication and associated clinical manifestations upon suppression of the immune system.
Previous research has shown that ferrets receiving a mixture of immunosuppressive drugs that
are also routinely given to humans undergoing solid organ transplantation, had reduced anti-
body responses following virus infection and deficient lymph node formation, indicating that
the immune defense was weakened [5, 27]. It was further shown that, similar to humans,
immunocompromised ferrets infected with A/H1N1pdm09 virus had prolonged virus replica-
tion compared to immunocompetent ferrets. Treatment of these ferrets with Oseltamivir led
to the rapid emergence of viruses with the H275Y NAI resistance substitution in NA [5].
Given that besides A/H1N1pdm09 viruses also A/H3N2 influenza viruses are circulating in
nearly every winter season [28, 29], the question arose whether the results observed in immu-
nocompromised ferrets infected with A/H1N1pdm09 would also be applicable to infection
with A/H3N2 virus. Therefore, the present study compared the course of infection of A/H3N2
viruses in immunocompetent and immunocompromised ferrets. It was found that immuno-
compromised ferrets inoculated with A/H3N2 viruses had prolonged presence of viral RNA in
the upper and lower respiratory tract and that the treatment of these ferrets with Oseltamivir
resulted in the rapid emergence of the resistance substitution R292K in NA. Mutation specific
real-time PCR and Illumina next generation sequencing (NGS) revealed that resistance muta-
tions were detected with a low frequency as early as 2 days after inoculation, which later
increased over time. Additional minor variants detected by Illumina NGS present in the HA
and NA genes were not associated with Oseltamivir treatment. The immunocompromised fer-
ret model for A/H3N2 virus captures several features of influenza virus infection and antiviral
drug treatment in immunocompromised humans, and may be useful for future preclinical
studies on antiviral drug therapies.
Material and methods
Viruses
An Oseltamivir-sensitive influenza A/H3N2 virus A/Netherlands/16/1998 (A/NL/16/98) was
used in this study. This virus was isolated from a respiratory specimen upon inoculation of a
Madin-Darby Canine Kidney (MDCK) cell culture (van Baalen et al. 2014). Biological clones
were obtained by plaque purification. A clone with a genome sequence identical to the consen-
sus sequence of the original specimen was used as the inoculum.
Ferrets
The animal experiment was performed in strict compliance with the European guidelines (EU
directive on animal testing 2010/63/EU) and Dutch Legislation (Experiments on Animals Act,
2014). An independent animal experimentation ethical review committee, Stichting Dier
Experimenten Commissie Consult, approved the animal studies (EMC-3137; protocol 122-13-
13). Eleven-month-old purpose-bred male ferrets were used, which were seronegative for
Aleutian disease and circulating influenza viruses (A/H1N1, A/H3N2 and B). The animals
were kept in standard housing until the start of the experiment. Four days before inoculation,
the animals were transferred to negatively pressured isolator cages at animal biosafety level 3.
Influenza A/H3N2 virus in immunocompromised ferrets and emergence of antiviral resistance
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Animals were sedated during animal handling using a mixture of ketamine (4 to 8 mg/kg)
(Henry Schein Animal Health BV, Cuijk, The Netherlands) alone or in combination with
medetomidine (0.1 mg/kg) (Henry Schein Animal Health BV, Cuijk, The Netherlands), which
was antagonized by the administration of atipamezole (0.1 mg/kg) (Henry Schein Animal
Health BV, Cuijk, The Netherlands) afterwards. Euthanasia under anesthesia was performed
by exsanguination. Health status and animal behavior was checked twice daily and included
the following parameters: weight loss, loss of appetite, degree of gastroenteritis, breathing
problems and strong abnormal behavior. Commercial food pellets and water were provided ad
libidum during the entire course of the experiment.
Immunosuppressants, antibiotics and antiviral drugs
The following immunosuppressive drugs were used to suppress the immune system of the
animals: Mycophenolate mofetil (MMF) powder for infusion (20mg/kg) (CellCept, Roche,
Woerden, The Netherlands), tacrolimus concentrate for infusion (5 mg/ml) (Prograft, Astellas
Pharma BV, Leiderdorp, The Netherlands) and oral solution of prednisolone sodium phos-
phate (5 mg/ml) (Hospital Pharmacy, UMCN St Radboud, Nijmegen, The Netherlands). This
regimen is similar to the immunosuppressive treatment of patients undergoing solid organ
transplantation. To prevent opportunistic infections, all animals received an antibiotic prophy-
laxis of amoxicillin supplemented with oral suspension of clavulanic acid (250 mg and 62.5 mg
per 5 mL, respectively) (Pharmachemie BV, Haarlem, The Netherlands). Oseltamivir phos-
phate (OSP; 10mg/Kg) was added to the regimes of ferrets receiving antiviral therapy and was
provided by Hoffman-La Roche LtD. (Tamiflu, Basel, Switzerland). Preparation of the drugs
was done as previous described [5].
Experimental groups and administration of the drugs
Twenty-four ferrets were randomly assigned into four groups (n = 6) (group 1: immunocom-
petent, group 2: immunocompromised, group 3: immunocompromised receiving Oseltamivir
and group 4: immunocompetent receiving Oseltamivir). A scheme of the experiment is
depicted in S1 Fig. At day -4, antibiotics (10 mg/kg amoxicillin and 2.5 mg/kg clavulanic acid)
were administered orally once daily to animals in all groups. Starting at day -3, ferrets in
groups 2 and 3 were administered a dose of the oral immunosuppressant cocktail (20 mg/kg
MMF, 0.5 mg/kg, tacrolimus and 8 mg/kg prednisolone) twice daily. Twenty-four hours after
virus inoculation, ferrets in groups 3 and 4 started receiving an oral solution of OSP (10 mg/
kg) once daily. Ferrets in groups 1, 2 and 3 were euthanized by exsanguination 18 days post
infection. The immunocompetent ferrets in group 4, which received OSP were euthanized on
day 7 after inoculation.
Virology
At day 0, all ferrets were inoculated intranasally and intratracheally with 104 TCID50 of A/NL/
16/98. Nose and throat swabs were collect daily in 3 ml virus transport medium [30]. RNA was
extracted from these samples and virus load was determined using the semi-quantitative real-
time reverse transcription polymerase chain reaction (qRT-PCR) targeting the matrix gene
segment. Oseltamivir resistance substitutions at amino acid positions 292 (R/K) and 119 (E/V)
of NA were monitored using a mutation specific RT-PCR (msRT-PCR) as described [31]. An
electron-microscopy-counted influenza A/PR/8/34 virus stock (Advanced Biotechnologies
Inc., Maryland, USA) was run in parallel to convert cycle thresholds to virus particle counts
(viral RNA copies). Blood samples for serum were taken on day 0 and day 13 post infection.
Serum influenza antibody titers against the homologous influenza strain A/Netherlands/16/
Influenza A/H3N2 virus in immunocompromised ferrets and emergence of antiviral resistance
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1998 and the heterologous strain A/Netherlands/271/1995 were determined by hemagglutina-
tion inhibition (HI) assay as previously described [32].
Next generation sequencing
RNA was extracted from throat and nose samples taken 2, 4, 6, 8 and 10 days post inoculation
(dpi), from immunocompromised and immunocompetent ferrets treated with Oseltamivir
(groups 3 and 4), using the QIAamp Viral RNA Mini Kit (Qiagen, Hilden, Germany). Subse-
quently, RNA sample volumes were reduced by evaporation in a SpeedVac at 65˚C and first-
strand cDNA was made using SuperScript III reverse transcriptase (Invitrogen, California,
USA) and random primers (ThermoFisher Scientific, Massachusetts, USA) according to the
manufacturer’s protocol. Second strand cDNA was synthesized in NEBnext second strand syn-
thesis reaction buffer with second strand enzyme mix (New England Biolabs, Massachusetts,
USA) and nuclease-free water. The cDNA was concentrated using the Genomic DNA Clean &
concentrator kit (Zymo Research, California, USA) according to the manufacturer’s instruc-
tions. The DNA products were quantified using the Qubit dsDNA BR Assay kit (Thermo
Fisher Scientific, Massachusetts, USA).
The enrichment, hybridization, Illumina library preparation of the HA and NA gene targets
were performed according to the protocol previously described by Eckert et al. [33]. Sequenc-
ing with a paired-end read length of 300 nucleotides (nt) was conducted on an Illumina MiSeq
instrument using the 600-cycle MiSeq Reagent Kit v3 (Illumina, California, USA).
Sequence reads were imported into CLC genomic Workbench version 8 (Qiagen) and
trimmed using a quality score cut-off of Q30. The trimmed reads were then mapped against
the HA and NA sequences of influenza virus A/Netherlands/5/1998 (GenBank Accession
numbers, CY114485 and CY114487). Nucleotide substitutions that resulted in an amino acid
substitution relative to the reference sequence of A/Netherlands/5/98 were called if the nucleo-
tide position was covered in more than a 100 reads, with an average quality score of 30 and a
forward and reverse balance of0.4. The substitutions that varied within the samples and had
a frequency above 1% were reported in the results tables.
Statistical analysis
All data is reported as the mean ± standard error of the mean (s.e.m.). The area under the
curve (AUC) of the virus load determined by qRT-PCR was calculated for each ferret group
using the trapezoid rule with graphpad prism. The student t-test was used to compare AUC
values between the groups. Data were considered significant if the P value was below 0.05.
Results
Prolonged viral RNA presence in immunocompromised ferrets
Ferrets were treated with a cocktail of mycophenolate mofetil, tacrolimus and prednisolone
sodium phosphate for 3 days, which was previously shown to cause a steady-state of severe
immunosuppression, which was continued by bi-daily dosing until the end of the experiment
(S2 Fig) [5, 30]. These immunosuppressed ferrets and immunocompetent control animals
were inoculated with 104 TCID50 A/NL/16/98 (H3N2) influenza virus. Viral RNA was detected
from 1 dpi onwards in the nose and the throat of the ferrets, reaching a peak around 3 dpi (Fig
1A and 1C). In the first week after inoculation, the virus loads were similar between untreated
immunocompetent and immunocompromised ferrets. However, immunocompetent ferrets
started to clear the infection from 7 dpi onwards with total virus clearance by 14–15 dpi, while
immunocompromised ferrets continued to shed viral RNA throughout the course of the
Influenza A/H3N2 virus in immunocompromised ferrets and emergence of antiviral resistance
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experiment (18 days). One group of immunocompromised ferrets inoculated with A/NL/16/
98 was treated with Oseltamivir starting at 1 dpi. In this group of ferrets, viral RNA was
detected in the throat and nose throughout the 18 days of the experiment, as in ferrets that
were not treated with Oseltamivir. The RNA virus load in the throat swabs of immunocompro-
mised ferrets were very similar with or without Oseltamivir treatment while virus loads were
substantially lower in the nose swabs of immunocompromised animals treated with Oseltami-
vir, in particular in the early phase (1–10 dpi) of the infection.
To determine the total amount of viral RNA that was present in the nose and throat swabs
of ferrets, the area under the curve (AUC) was calculated for all groups (Fig 1B and 1D). The
total amount of virus shedding from both the throat and the nose of untreated immunocom-
promised ferrets was significantly higher as compared to the throat and nose of immunocom-
petent ferrets (P<0.001). Treatment of immunocompromised ferrets with Oseltamivir
resulted in significantly lower virus shedding from both the nose and throat compared to
untreated immunocompromised ferrets. The reduction of virus shedding from the throat of
Fig 1. Viral RNA load in ferrets inoculated with influenza virus A/NL/16/98. Immunocompetent (blue) and immunocompromised (red,
green) ferrets were inoculated with influenza virus A/NL/16/98 (H3N2) and subsequently treated with Oseltamivir (green) or left untreated
(blue, red). Virus RNA load in samples of the throat (A) and nose (C) was determined by qRT-PCR daily for 18 days. The area under the curve
of panels A and C was used to estimate the total amount of viral RNA shedding from the throat (B) and nose (D) of the inoculated ferrets. The
line and bar graphs depict the mean ± S.E.M. The asterisks indicates a statistically significant P value (P<0.001).
https://doi.org/10.1371/journal.pone.0200849.g001
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immunocompromised ferrets as a consequence of Oseltamivir treatment was relatively modest
as compared to the reduction of virus shedding from the nose.
In a separate experiment, immunocompetent ferrets inoculated with influenza virus A/NL/
16/98 were also treated with Oseltamivir, but only for 7 days. The levels of virus shedding from
the nose and throat of these animals were similar to those of immunocompromised ferrets
treated with Oseltamivir, as were the total amounts of viral RNA as calculated from the AUC
(S3 Fig).
Emergence of Oseltamivir resistant viruses in immunocompromised ferrets
treated with Oseltamivir
Samples from all inoculated animals (Fig 2 and S3 Fig) were analyzed by mutation-specific
RT-PCR to detect substitutions E119V and R292K in NA, the most common Oseltamivir asso-
ciated resistance mutations in A/H3N2 influenza viruses [34]. Mutation E119V was not
detected in these samples, whereas the R292K resistance mutation was detected in the nose
and throat swabs of all immunocompromised (Fig 2C) ferrets that were treated with Oseltami-
vir. In contrast, emergence of viruses with resistance mutations did not occur in any of the
untreated immunocompetent and immunocompromised ferrets, indicating that resistance
mutations did not emerge spontaneously. The R292K substitution first emerged in the throat
Fig 2. Emergence of Oseltamivir resistant viruses in ferrets. The emergence of Oseltamivir resistant viruses was monitored in throat
and nose samples from untreated immunocompetent ferrets (A), untreated immunocompromised ferrets (B) and Oseltamivir treated
immunocompromised ferrets (C) by mutation-specific RT-PCR for the Oseltamivir-resistance mutation R292K. The green bars depict the
presence of the wildtype genotype (292R) and the magenta the presence of the resistant genotype (292K). If both genotypes were present in one
sample, the proportions of the genotypes are stacked.
https://doi.org/10.1371/journal.pone.0200849.g002
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at 5dpi in one animal (ferret 4) and at 6dpi and 7dpi in three (ferret 1, 2, 3) and two animals
(ferret 5 and 6) respectively. When the R292K substitution occurred, it was initially present as
a minor genotype in a mixed population of wild type and resistant viruses. At later time points,
viruses with the resistance mutation represented the major genotype and frequently even the
only genotype in the virus population (Fig 2C). In two immunocompromised ferrets that were
treated with Oseltamivir, virus was cleared from the nose and throat by 10–11 dpi. However,
there was no difference in the emergence of Oseltamivir resistance mutations in viruses of ani-
mals that did (ferret 2 and 3) or did not (ferret 1, 4, 5, 6) clear the virus earlier (Fig 2C). There
were no substantial differences in the kinetics of emergence of Oseltamivir resistance muta-
tions in immunocompetent ferrets treated with Oseltamivir as compared to immunocompro-
mised ferrets, although resistant viruses were not detected in one of the animals in this short
time-course experiment (S4 Fig).
Lack of detection of additional mutations associated with Oseltamivir
treatment
Illumina NGS was conducted to analyze the emergence of mutations beyond R292K that were
potentially associated with Oseltamivir treatment in the HA and NA genes of influenza viruses
in immunocompetent and immunocompromised ferrets at 2, 4, 6, 8 and 10 dpi. To validate
this approach, the frequency of the R292K resistance substitutions was first determined by Illu-
mina NGS. There was good overall correspondence between the relative proportion of the
R292K resistance substitution as determined by msRT-PCR and Illumina NGS (S5 Fig, R2 =
0.94, P<0.0001). For some ferrets, the resistance mutation was already detected at 4 dpi at a
low frequency by Illumina NGS, when it was not yet detected by msRT-PCR (S5 Fig). Like the
msRT-PCR analysis, Illumina NGS allowed the detection of R292K in all immunocompro-
mised and immunocompetent ferrets treated with Oseltamivir (Fig 3 and S6 Fig) (Table 1 and
S1 Table).
Illumina NGS revealed numerous mutations in HA and NA of the viruses beyond R292K,
present in all Oseltamivir treated animals (Table 1, S1 Table). Minor variants with frequencies
ranging from 1.0–7.7% were detected in the HA or NA genes in samples from all ferrets but
one. In some ferret samples, such HA and NA mutations became predominant, but only tem-
porarily. Examples of substitutions are NA-T242I (ferret 1 at 10 dpi) and HA-T151A (ferret 3
at 10 dpi) (Table 1). However, where viruses with the R292K substitution in NA generally
increased in prevalence throughout the course of the experiment, to become dominant at the
latest time points, none of the additional substitutions followed a similar trend. Thus, under
these experimental conditions, the emergence of viruses with the R292K substitution in NA
was not accompanied by co-mutations in NA and HA that could act to compensate for poten-
tial fitness losses associated with Oseltamivir resistance.
Discussion
Here, the immunocompromised ferret model for influenza A virus infection and Oseltamivir
treatment that was recently described for A/H1N1pdm09 virus infection [5] was evaluated for
infection with an influenza A/H3N2 virus. The immune suppressive regimen employed in this
immunocompromised ferret model mimics the regimen used for solid organ transplant recipi-
ents. Like A/H1N1pdm09 influenza virus, influenza A/H3N2 viruses continue to cause annual
epidemics with substantial morbidity and mortality, for which NAI are used routinely as anti-
viral drugs, in particular in individuals with an impaired immune response.
Although the level of immunosuppression was not addressed directly in the present study,
in previous studies it was shown that this ferret model results in immunosuppression as
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evidenced by lower influenza specific HI antibody titers, impaired formation of the lymphoid
follicles present in the tracheobronchial lymph nodes and depletion of lymphocytes in the ton-
sils of the ferrets [5]. Moreover, it was shown that the immunocompromised ferrets had sus-
tained A/H1N1pdm09 virus shedding compared to the immunocompetent ferrets.
Accordingly, similar to influenza virus infection in immunocompromised patients, the present
data showed that influenza A/H3N2 viral RNA was detected for a longer period in immuno-
compromised ferrets compared to the immunocompetent ferrets [5, 8]. Apparently, the
immune response of the ferrets receiving the immunosuppressive drugs was not effective in
clearing the virus infection, leading to more prolonged virus presence in the immunocompro-
mised host. This indicated that immunocompromised ferrets might represent a suitable model
to analyze virus shedding in immunocompromised hosts.
The effect of NAI such as Oseltamivir against influenza virus infection in immunocompro-
mised patients has been controversial, where some clinical studies showed that Oseltamivir
was effective to reduce disease burden, viral shedding, symptom severity, length of hospital
stay and mortality, while others claimed that it had no or minimum beneficial effects [14, 35–
39]. The current data showed that the treatment of both immunocompromised and immuno-
competent ferrets with Oseltamivir resulted in a lower total A/H3N2 viral RNA load in the
nose and the throat samples compared to the ferrets that were untreated [6]. Interestingly, this
reduction of viral RNA in Oseltamivir treated animals was larger in the nose compared to the
throat. Oseltamivir has been shown to reduce viral replication in the nose of influenza A/
H5N1 and A/H1N1pdm09 infected ferrets [40–42]. However, throat samples were not taken
from the ferrets in these studies. Therefore, it is not known whether the reduction of viral rep-
lication in the upper respiratory tract was higher compared to that in the lower respiratory
Fig 3. The frequency of the R292K mutation as determined by Illumina NGS in Oseltamivir treated
immunocompromised ferrets. The percentage of the R292K variant was determined in pooled throat/nose samples
collected at 2, 4, 6, 8 and 10 dpi from immunocompromised ferrets that received Oseltamivir treatment. The graph
depicts the frequency of the R292K mutation over time for each ferret separately, with circles, squares, triangles, down
triangles, diamonds and open circles representing ferrets 1–6 respectively.
https://doi.org/10.1371/journal.pone.0200849.g003
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tract upon Oseltamivir treatment of ferrets, which is largely reflected by viral replication in the
nose and throat swabs respectively. The difference seen in total viral RNA load in the nose and
throat upon Oseltamivir treatment could be due to a difference in the Oseltamivir concentra-
tion that is present in these areas of the respiratory tract. Additionally, since viral RNA loads
peaked earlier in the throat of the ferrets compared to the nose, it is also possible that Oseltami-
vir treatment has to accommodate with higher amounts of virus compared to the nose, as
Table 1. Amino acid substitution in hemagglutinin and neuraminidase sequences of OS treated immunocompro-
mised ferrets by Illumina next generation sequencing.
Ferret Daya R292K
(%)
AAb change in HAb (%) AA change in NAb (%)
1 2 0
4 0 L29P(2.1), A85T(8.3), F516L(2.5) V424G(1.0)
6 49.9 D120N(1.1), V418F(1.1) I26T(1.5), V30A(5.7), V33A(2.0), Y40H
(2.6), C42R(2.6), V50A(2.3), I57T(2.2), I62T
(1.9), L140I(1.4)
8 76.2 N329T(1.5)
10 44.1 F15S(1.6), N440K(1.2) N47D(1.8), T242I(25.0)
2 2 0 T34I(1.3)
4 9.6 S281R(1.9), M284I(1.2), D287A(1.2),
F348L(1.3), E442G(1.5)
P46L(1.0), G286D(1.4)
6 67.2 K308N(1.0)
8 80.5 P126S(1.4)
10 98.9
3 2 0 P285L(1.8)
4 0.8 G132D(1.3), R508G(1.4)
6 14.8 S165N(1.0), S225R(2.5), I246M (4.4),
S263N(4.8), F274S(1.8), I276T(1.1), R323K
(3.9), E442G(1.8)
8 67.9 T26(7.3), D69N(1.1), N205I(1.2), A214V
(1.4), I242F(1.3), A320V(1.1), A350T(1.1)
10 94.5 F95L(1.4), T151A(25.2) E83K(1.0), I222N(1.4)
4 2 0
4 4.0 T386I(2.0), M478I(1.0) I28V(4.6), T34A(3.0), L52M(2.0)
6 77.1 A6S(1.0), F536L(1.5), F550S(2.5) I62T(1.1), T69N(1.1), D309G(1.5)
8 57.6 F95L(2.2), T151A(1.3) D83K(1.2)
10 0
5 2 0 D120N(1.5), A537V(1.9)
4 2.6 C30R(2.6), K403N(1.5)
6 1.8 G21R(6.6), G21V(3.2), S111G(6.9), E442G
(5.7), L463Q(2.0)
8 57.7 H200P(1.1) N208S(1.2)
10 69.7 A320P(1.3), L443F(1.0)
6 2 0
4 0 P324S(1.8), E419G(5.3) T195A(1.5), T242I(1.9), D330E(3.8)
6 0 P119A(1.6), R472K(1.5)
8 0
10 89.8 N232S(1.6)
a Time after inoculation when resistance mutations is detected.
b Abbreviation: AA, amino acid; HA, hemagglutinin; NA, neuraminidase.
Mutations with a frequency above 20% are marked in bold.
https://doi.org/10.1371/journal.pone.0200849.t001
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studies have shown that virus inhibition by Oseltamivir is less efficient at higher virus titers
[40, 43, 44]. Therefore, the distribution of Oseltamivir throughout the respiratory tract of the
ferret is essential to reduce viral replication efficiently, which remains to be elucidated. Even
though there was a reduction in total viral RNA upon Oseltamivir treatment, this did not lead
to complete viral clearance, as viral RNA was still present at 18 dpi in immunocompromised
ferrets. This was in accordance with a previous study demonstrating that immunocompro-
mised ferrets inoculated with A/H1N1pdm09 still had prolonged viral shedding upon treat-
ment with Oseltamivir [5]. In the present study, none of the ferrets died during the course of
the experiment or developed severe disease, hence no conclusions can be drawn about the
effectiveness of Oseltamivir in reducing morbidity and mortality. In the previous study with
A/H1N1pdm09 virus, Oseltamivir treatment was found to decrease mortality in immunocom-
promised ferrets [5].
Oseltamivir treatment led to the emergence the R292K substitution in immunocompro-
mised and immunocompetent ferrets inoculated with A/H3N2 virus. The resistant R292K
genotype of the A/H3N2 virus was detected initially as a minor variant by msRT-PCR. With
Illumina NGS, resistance mutation R292K was already detected at 4 dpi in Oseltamivir treated
ferrets. None of the immunocompetent and immunocompromised ferrets had acquired the
E119V, although this is also a common mutation associated with Oseltamivir treatment that is
found in NA. The E119V mutation was found to cause a 20 to 1000-fold increase in the 50%
inhibitory concentration (IC50) of Oseltamivir [45, 46]. The R292K substitution was found to
cause a greater reduction in susceptibility to Oseltamivir compared to the E119V substitution,
conferring a> 9000 increase of the Oseltamivir IC50 [45, 46]. Plasma levels of Oseltamivir
have been shown to reach approximate concentrations between 2561 and 9603nM in ferrets
[5], which is higher than the IC50 associated with the E119V mutation. This could explain why
the E119V mutation was not detected in the present study.
Previous studies have shown that the emergence of resistance mutations impaired the
fitness of influenza viruses but that additional mutations may be acquired in HA or NA to
compensate for this fitness loss [47–49]. This is relevant as the prolonged viral shedding in
immunocompromised hosts could allow expansion of the quasi-species of influenza viruses
present in the host due to the error prone viral replication. This in combination with Oseltami-
vir treatment creates a strong selective pressure on the influenza virus variant population and
facilitates the emergence of resistant virus as a dominant variant in the population, if needed
upon acquisition of additional–compensatory–mutations. In immunocompetent patients the
resistant viruses may be cleared before they acquire such compensatory substitution. The pres-
ence of such resistant viruses that have regained full viral fitness may negatively impact the effi-
cacy of the Oseltamivir treatment and account for the sustained virus shedding in the ferrets,
even after the reduction of the total virus load. Three immunocompromised ferrets in the pres-
ent study acquired additional substitutions in the HA (T151A) and the NA (T242I) proteins
besides the R292K resistance substitution, which could represent compensatory changes. The
substitution T151A in HA is not common in circulating viruses in the human population, as
it is not present in the HA sequences in the Global Initiative on Sharing All Influenza Data
(GISAID) Epiflu database. The T242I substitution in NA has previously only been detected in
an immunocompromised child infected with multidrug resistant A/H3N2 virus [24]. The sub-
stitution was present together with the known E119V and I222V resistance substitutions.
Therefore, this substitution may be associated with antiviral treatment and might have a com-
pensatory function. However, in the immunocompromised child it was only detected in one
clinical sample and did not become fixed in the virus population, suggesting that it may have
emerged by chance and was not involved in determining antiviral resistance. Future experi-
ments may be conducted to study the function of the substitution on the virus phenotype by
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reverse genetics. The other substitutions in HA (T151A) and NA (I57T) have not been identi-
fied in previous studies and their functions remain unknown.
Individuals with suppressed immunity due to age, pregnancy, disease or treatment with
immunosuppressive drugs are susceptible to various virus infections beyond influenza, which
can lead to high morbidity and mortality [4, 7, 16, 50]. The search for ideal medications to
treat these various viral infections in immunocompromised patients will lead to the same chal-
lenges as faced with the development of anti-influenza viral treatments. The immunocompro-
mised ferret model may be further developed to analyze other viral infections that occur in
immunocompromised patients and to design novel drugs to treat them. For instance, Stittelaar
et al. demonstrated that ferrets with a suppressed immunity were susceptible to human respi-
ratory syncytial virus (HRSV) infection and that the virological outcome observed in these fer-
rets mimicked the increased virus loads and sustained virus infection seen in humans [27].
Moreover, they showed that the prophylactic treatment of HRSV-infected immunocompro-
mised ferrets with Palivizumab temporarily reduced virus replication, but it resulted in
increased virus load (25). Thus, the immunocompromised ferret model is a suitable model to
evaluate virus infections in immunocompromised hosts as well as specific intervention strate-
gies for these viruses.
In conclusion, the present study demonstrated that the immunocompromised ferret model
can be used to study virus shedding of influenza A/H3N2 virus. The immunocompromised
ferret model is a promising model to study the duration of virus shedding and the efficacy of
novel mono and combination antiviral treatments for immunocompromised humans. In com-
bination with msRT-PCR and Illumina NGS, this model may also be used to evaluate the
chance of developing and selecting mutations associated with drug resistance, direct and com-
pensatory, in immunocompromised hosts.
Supporting information
S1 Fig. Scheme of time of treatment start and virus inoculation in ferrets of the 4 experi-
mental groups. Four days before virus inoculation, all ferrets were given a cocktail of antibi-
otics (10 mg/kg amoxicillin and 2.5 mg/kg clavulanic acid) once daily till the end of the
experiment. The ferrets assigned to the immunosuppressive groups (group 2 and 3) were
given a mixture of immunosuppressant (20 mg/kg MMF, 0.5 mg/kg, tacrolimus and 8 mg/kg
prednisolone) starting 3 days prior to virus inoculation twice daily till the end of the experi-
ment. All ferrets were inoculated on day 0 with 104 TCID50 A/NL/16/98 (H3N2) influenza
virus. One day after virus infection, OSP (10 mg/kg) was administered to ferrets from group 3
and 4. Ferrets from groups 1, 2 and 3 were euthanized 18 days post infection and the once
from group 4 were euthanized 7 days post infection.
(PDF)
S2 Fig. Influenza antibody titers of immunocompetent and immunocompromised ferrets
against influenza viruses A/NL/16/98 and A/NL/271/95. Serum influenza antibody titers of
the untreated immunocompetent and immunocompromised ferrets against the influenza
homologous strain (A) A/NL/16/98 and (B) the heterologous strain A/NL/271/95 of immuno-
competent and immunocompromised ferrets were determined by hemagglutinin inhibition
(HI) assay. The antibody titer of each animal are depicted as individuals points. The horizontal
bars represent the mean ± S.E.M.
(PDF)
S3 Fig. Viral RNA load in ferrets inoculated with influenza virus A/NL/16/98. Immuno-
competent (blue, purple) and immunocompromised (red, green) ferrets were inoculated with
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influenza virus A/NL/16/98 (H3N2) and subsequently treated with oseltamivir (green, purple)
or left untreated (blue, red). Virus RNA load in samples of the throat (A) and nose (C) was
determined by qRT-PCR daily for 7 days. The area under the curve of panels A and C was
used to estimate the total amount of viral RNA shedding from the throat (B) and nose (D) of
the inoculated ferrets. The line and bar graphs depict the mean ± S.E.M. The asterisks indicates
a statistically significant P value (0.01<P>0.001, P<0.001).
(PDF)
S4 Fig. Emergence of oseltamivir resistant viruses in ferrets. The emergence of oseltamivir
resistant viruses was monitored in throat and nose samples from untreated immunocompetent
ferrets (A), untreated immunocompromised ferrets (B), oseltamivir treated immunocompro-
mised ferrets (C) and treated immunocompetent ferrets (D) by mutation-specific RT-PCR for
the oseltamivir-resistance mutation R292K. The green bars depict the presence of the wildtype
genotype (292R) and the magenta the presence of the resistant genotype (292K). If both geno-
types were present in one sample, the proportions of the genotypes are stacked.
(PDF)
S5 Fig. Correspondence between the R292K resistance mutation as measured by mutation
specific RT-PCR and Illumina next generation sequencing. The relative proportion of the
R292K resistance mutation detected in samples of all oseltamivir treated immunocompro-
mised (grey circles) and immunocompetent (open squares) ferrets inoculated with A/NL/16/
98 (H3N2) as determined by mutation specific RT-PCR was compared to the relative propor-
tion determined by Illumina NGS.
(PDF)
S6 Fig. The frequency of the R292K mutation as determine by Illumina next generation
sequencing in oseltamivir treated immunocompetent ferrets. The percentage of the R292K
variant was determined in pooled throat/nose samples collected at 2, 4, 6, 8 and 10 dpi from
immunocompetent ferrets that received oseltamivir treatment. The graph depicts the fre-
quency of the R292K mutation over time for each ferret separately, with circles, squares, trian-
gles, down triangles, diamonds and open circles representing ferrets 1–6 respectively.
(PDF)
S1 Table. Amino acid substitution in hemagglutinin and neuraminidase sequences of OS
treated immunocompetent ferrets by Illumina next-generation sequencing.
(PDF)
S1 File. ARRIVE guidelines checklist.
(PDF)
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